Association of Beta-Blocker Therapy at Discharge With Clinical Outcomes in Patients With Actue Coronary Syndrome

Association of Beta-Blocker Therapy at Discharge With Clinical Outcomes in Patients With Actue Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03658577

Enrollment

582

Registered

2018-09-05

Start date

2018-03-02

Completion date

2023-12-31

Last updated

2018-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Actue Coronary Syndrome

Keywords

Actue Coronary Syndrome, Beta-Blocker, Percutaneous Coronary Intervention

Brief summary

Limited data are available on the efficacy of beta-blocker therapy for secondary prevention in Actue Coronary Syndrome(ACS) patients. This study sought to investigate the association of beta-blocker therapy at discharge with clinical outcomes in patients with ACS after percutaneous coronary intervention (PCI).

Detailed description

The American College of Cardiology (ACC)/American Heart Association (AHA) guidelines recommend beta-blockers for secondary prevention in patients with ACS without regard to reperfusion therapy. However, evidence supporting this recommendation originated from studies conducted before the introduction of reperfusion therapy or studies in patients treated with fibrinolysis. In the present era of PCI, there are no prospective randomized studies looking at the effects of long-term beta-blocker therapy on clinical outcomes in ACS patients. Moreover, results from registry data and post-hoc analysis on beta-blocker therapy in patients undergoing PCI are inconsistent. In particular, the beneficial effect of long-term beta-blocker therapy has not been well established in patients with relatively low risk, such as preserved left ventricular systolic function or single-vessel disease. Therefore, we investigated the association of beta-blocker therapy at discharge with clinical outcomes in ACS patients after PCI.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. consecutive patients 18 years of age or older; 2. patients diagnosed as ACS(including STEMI、NSTEMI and UA) by doctor at discharge; 3. patients undergoing primary PCI.

Exclusion criteria

missing beta-blocker information.

Design outcomes

Primary

Measure	Time frame	Description
all-cause death	3 years	The primary outcome was all-cause death during follow up.

Secondary

Measure	Time frame	Description
MACE	3 year	Secondary outcomes included major adverse cardiac events (MACE), a composite of cardiac death, myocardial infarction, stroke, any revascularization during follow-up

Countries

China

Contacts

Primary ContactFeng Lin, MD

119538892@qq.com+8613510730251

Backup ContactXia Liu, PhD

lf.sakula@qq.com+8613602552203

Outcome results